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ABSTRACT Following antiretroviral therapy, HIV-infected patients show increased
circulating levels of the antidiabetic hormone ﬁbroblast growth factor 21 (FGF21). In
contrast, the expression of the FGF21-obligatory coreceptor -Klotho (KLB) is re-
duced in target tissues. This situation is comparable to the FGF21 resistance status
observed in obesity and type 2 diabetes. Here, we performed the ﬁrst systematic
study of the effects of distinct members of different antiretroviral drug classes on
the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells. Most
protease inhibitors and the nonnucleoside reverse transcriptase inhibitor efavirenz
induced FGF21 gene expression. Neither nucleoside reverse transcriptase inhibitors
nor the viral entry inhibitor maraviroc had any effect. Among the integrase inhibi-
tors, elvitegravir signiﬁcantly induced FGF21 expression, whereas raltegravir had mi-
nor effects only in adipose cells. In human hepatocytes and adipocytes, known tar-
get cells of FGF21 action, efavirenz, elvitegravir, and the lopinavir-ritonavir combination
exerted inhibitory effects on KLB gene expression. Drug treatments that elicited
FGF21 induction/KLB repression were those found to induce endoplasmic reticulum
(ER) stress and oxidative stress. Notably, the pharmacological agents thapsigargin
and tunicamycin, which induce these stress pathways, mimicked the effects of drug
treatments. Moreover, pharmacological inhibitors of either ER or oxidative stress sig-
niﬁcantly impaired lopinavir–ritonavir-induced regulation of FGF21, but not KLB. In
conclusion, the present in vitro screen study identiﬁes the antiretroviral drugs that
affect FGF21/KLB expression in human cells. The present results could have impor-
tant implications for the management of comorbidities resulting from side effects of
speciﬁc antiretroviral drugs for the treatment of HIV-infected patients.
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Successful treatment of HIV-infected patients with antiretroviral therapies (ART) haslargely transformed HIV infection to a chronic medical condition (1). ART regimens
can achieve strong virological control, but long-term exposure to ART, as often occurs
in the growing population of older HIV patients, results in increased metabolic com-
plications (2). Insulin resistance, metabolic syndrome, enhanced cardiovascular risk, and
even overt lipodystrophy are common alterations in ART-treated HIV-infected patients
(3). Several classes of antiretroviral drugs appear especially likely to elicit these altera-
tions. For example, nucleoside analogs such as zidovudine and stavudine, which inhibit
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reverse transcriptase, appear to particularly exacerbate lipodystrophy, whereas pro-
tease inhibitors (PIs) have been implicated in altered glucose homeostasis (4). The
molecular mechanisms that account for these toxicities are incompletely understood.
More recently developed drugs (i.e., integrase inhibitors, viral entry inhibitors, and novel
reverse transcriptase inhibitors and PIs) appear less prone to cause overt lipodystrophy.
However, their impact on metabolic homeostasis in patients is still unclear (5).
Several studies on distinct cohorts of HIV patients have reported alterations in the
ﬁbroblast growth factor 21 (FGF21) endocrine system that manifest as abnormally high
levels of FGF21 (6–8). FGF21, a hormone that was recently found to play a key role in
glucose and lipid homeostasis, acts as an antidiabetic and possibly antiobesity factor
(9). Several recent pilot studies have reported improvement in lipidemia and body
weight after short-term treatment of obese/diabetic volunteers with FGF21 analogs (10,
11). Long-acting FGF21 analogs and agonists that mimic FGF21 action are under
investigation in clinical trials in patients with obesity and diabetes (ClinicalTrials regis-
tration no. NCT02413372, NCT02538874, NCT2593331, NCT02708576, and NCT03060538).
FGF21 is mainly produced in the liver and targets adipose tissue (and possibly that of the
liver as well), promoting glucose uptake and oxidation (12). The effects of FGF21 are
mediated by FGF receptors (FGFRs) that must interact with the cell surface protein
-Klotho (KLB) to form an FGF21-responsive receptor complex. Thus, the KLB corecep-
tor is essential for FGF21 action on target tissues (13). The paradoxically high FGF21
levels in HIV patients are associated with a downregulation of the molecular mediator
of cellular FGF21 action, KLB. This scenario, which is reminiscent of “FGF21 resistance,”
is analogous to the situation found in obesity and type 2 diabetes (14, 15). It has been
suggested that alterations in the FGF21 endocrine system involving liver and adipose
tissues could be a major mechanism responsible for eliciting metabolic alterations in
HIV patients (8, 13, 16). In this context, it has recently been reported that high FGF21
levels in HIV patients are signiﬁcantly associated with altered bone homeostasis (17),
consistent with previous indications of potential deleterious effects of high FGF21
levels on bone in experimental rodent models (18). Moreover, skeletal muscle, a tissue
that does not express signiﬁcant amounts of FGF21 in healthy individuals, shows
increased expression of FGF21 under conditions in which muscle experiences mito-
chondrial oxidative stress (16, 19, 20), and a recent study reported enhanced expression
of FGF21 in muscle from HIV patients in association with metabolic alterations (7).
Previous studies on distinct HIV patient cohorts have failed to show signiﬁcant
associations between abnormally high FGF21 levels and speciﬁc drugs included in ART
cocktails, possibly owing to the limited number of patients and diversity of ART regimens
prior to and during the study. However, several intracellular processes, including endoplas-
mic reticulum (ER) stress and oxidative stress, are known to induce hepatic expression of
FGF21 (21–23), and there are reports that several antiretroviral drugs or drug classes (e.g.,
efavirenz and PIs) promote such processes (24–26). To date, less is known about molecular
agents causing disturbances in the response to FGF21 in the target tissues. It has been
reported that proinﬂammatory signaling in adipose tissue negatively regulates KLB expres-
sion (27). Then, inﬂammation in adipose tissue, a common condition in obesity, diabetes,
and HIV lipodystrophy, may contribute to impaired FGF21 responsiveness in adipocytes.
Studies on the effects of antiretroviral drugs on human cells in culture have proven
to be useful for the initial in vitro assessment of the potential of drugs to disturb
metabolism (28–36). These studies have reported effects of several antiretroviral drugs
on adipogenesis, senescence, mitochondrial toxicity, and ER stress, but none investi-
gated their actions on the FGF21 system. In the present study, we hypothesized that
antiretroviral drugs could alter the FGF21/KLB system by affecting their expression in
human hepatic, adipose, and skeletal muscle cells. If so, this in vitro approach could be
used to screen currently used antiretroviral drugs for their potential risk to cause
FGF21/KLB toxicity. Here, we report a systematic analysis of the capacity of antiretroviral
drugs, both “classical” and recently developed, to cause alterations in the FGF21/KLB
system. That is, we analyzed their potential to promote FGF21 expression and KLB
downregulation—the two key events associated with a disturbed FGF21 system in
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patients—in human hepatic, adipose, and muscle cells. The effects of drug-induced ER
stress and oxidative stress on these alterations were also explored.
RESULTS
Effects of antiretroviral drugs on FGF21 and KLB expression in human hepatic
cells. To determine the possible effects of antiretroviral drugs on the FGF21 system, we
ﬁrst analyzed human hepatocytes, the main cellular source of FGF21 as well as a
potential cellular target of FGF21 action. Among the antiretroviral drugs tested in
HepG2 hepatic cells, all PIs, including the lopinavir-ritonavir 4:1 combination, elicited a
robust induction of FGF21 expression (Fig. 1A). Neither the classical nucleoside reverse
transcriptase inhibitors (NRTIs) zidovudine and stavudine nor the nucleotide analog
tenofovir altered FGF21 mRNA expression. Among nonnucleoside reverse transcriptase
inhibitors (NNRTIs), efavirenz markedly induced FGF21 expression, whereas neither
nevirapine nor rilpivirine showed signiﬁcant effects. Among integrase inhibitors (INS-
TIs), elvitegravir signiﬁcantly induced FGF21 expression, whereas raltegravir had no
effect. The viral entry inhibitor maraviroc also had no effect. A parallel assessment of the
effects of these drugs on KLB expression revealed a reciprocal pattern of alterations:
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FIG 1 Effects of antiretroviral drugs on the expression of FGF21, KLB, CHOP10, and HSPA5mRNAs and on FGF21 promoter activity in human hepatic HepG2 cells. Cells
were exposed, when indicated, to the following drugs: zidovudine (AZT), 100M; stavudine (D4T), 100M; tenofovir disoproxil fumarate (TDF), 5M; nevirapine (NVP),
20 M; efavirenz (EFV), 50 M; rilpivirine (RPV), 10 M; lopinavir-ritonavir 4:1 (LPV/r), 20 M; ritonavir (RTV), 20 M; lopinavir (LPV), 20 M; nelﬁnavir (NFV), 20 M;
atazanavir (ATV), 50 M; raltegravir (RAL), 50 M; elvitegravir (ELV), 50 M; maraviroc (MRV), 4 M; tunicamycin (TUN), 2 M; thapsigargin (THAP), 2 M. (A) mRNA
levels are presented as means SEM from 4 to 5 independent experiments and are expressed relative to values for control cells (deﬁned as 1). (B) FGF21 protein levels
in cell culturemedium. (C) Luciferase activity in HepG2 cells transiently transfected with plasmid constructs in which luciferase is driven by the1,497/5 (1.5 kb-Luc)
or77/5 (77 bp-Luc) 5= regions of the FGF21 gene. Cells were treated for 24 h with the indicated concentrations of drugs: EFV, 50 M; LPV/r, 20 M; THAP, 2 M.
Data are normalized to Renilla luciferase activity driven by the cotransfected pRL-CMV plasmid. Data are means  SEM from 4 to 5 independent experiments. *, P 
0.05; **, P  0.01, and ***, P  0.001 for each drug treatment versus control.
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most antiretrovirals that induced FGF21 (i.e., most PIs, efavirenz, and elvitegravir)
repressed KLB expression. KLB expression was unaffected by drugs that did not alter
FGF21 expression (Fig. 1A).
The induction of FGF21 and repression of KLB observed in response to PIs and
efavirenz, which are known to induce ER stress and oxidative stress in several cell types,
including hepatocytes (24, 26), prompted us to examine whether these drugs also
altered the expression of the genes encoding C/EBP-homologous protein 10 (CHOP10)
and heat shock protein 5 (HSPA5), markers of ER stress and/or oxidative stress (37, 38).
These analyses showed that the effects of drugs on CHOP10 and HSPA5 expression
markedly paralleled their effects on FGF21 expression, as evidenced by the signiﬁcant
upregulation of both CHOP10 and HSPA5 mRNAs in response to PIs, efavirenz, and
elvitegravir (Fig. 1A). In addition, we treated HepG2 cells with tunicamycin and thap-
sigargin, two known inducers of ER stress. Both agents strongly induced CHOP10 and
HSPA5 expression and elicited robust reciprocal effects on FGF21 expression (induction)
and KLB expression (repression)—the same effects produced by the aforementioned
antiretroviral drugs (Fig. 1A).
The main changes found for FGF21 mRNA expression were reﬂected in FGF21
protein levels released by cells to culture. Thus, efavirenz, the lopinavir-ritonavir com-
bination, and elvitegravir caused a signiﬁcant increase in FGF21 levels in HepG2 culture
medium, whereas raltegravir had no effect (Fig. 1B). The ER stress/oxidative stress
inducers tunicamycin and thapsigargin caused the highest induction in FGF21 protein
release by HepG2 cells (Fig. 1B).
After this initial screening, we evaluated the concentration dependence of the
effects of the drugs that had been found to alter the FGF21 system at a single relatively
high dose in the study above (see Fig. S1 in the supplemental material); raltegravir was
used as an ineffective drug control. Efavirenz, elvitegravir, and the lopinavir-ritonavir
combination caused reciprocal concentration-response effects, inducing FGF21 and
suppressing KLB. With one exception, we also found that these drugs induced a
concentration-dependent induction of CHOP10 and HSPA5 expression, similar to that
found for FGF21 induction and KLB repression. The exception was efavirenz, which
induced expression of ER stress/oxidative stress markers only at the highest concen-
tration tested (50 M), despite the fact that lower concentrations (20 M) were
sufﬁcient to alter FGF21 and KLB expression. Raltegravir did not alter FGF21 or KLB
mRNA expression, or CHOP10 or HSPA5 mRNA expression at any concentration tested.
To further assess FGF21 induction, we monitored the transcriptional activity of the
FGF21 promoter after transfecting HepG2 cells with an FGF21 promoter-luciferase
reporter construct in which luciferase activity is driven by the 5= region (1.5 kb) of the
FGF21 gene (Fig. 1C). These analyses showed that thapsigargin, the positive control for
ER stress induction, and the drugs efavirenz and lopinavir-ritonavir signiﬁcantly induced
FGF21 promoter activity; this effect was lost when transfections were performed using
a construct comprising the 77 bp site in which most of the 5= noncoding region of
the FGF21 gene was deleted. These results demonstrate that ER stress-inducing drugs
and antiretroviral drugs that elicit increased FGF21 mRNA expression act through the
induction of FGF21 gene transcription.
Effects of antiretroviral drugs on FGF21 and KLB expression in human adi-
pocytes. Next, we analyzed the effects of antiretroviral drugs on adipocytes, the main
cellular target of FGF21. Human Simpson-Golabi-Behmel Syndrome (SGBS) adipocytes
undergoing adipogenic differentiation were exposed to the panel of antiretroviral
drugs belonging to distinct classes. As was the case for hepatic cells, for this initial
screen, the drugs were used at concentrations known to be nontoxic in this cell type,
and FGF21 and KLBmRNA expression levels were determined. Under control conditions,
SGBS adipocytes expressed very low levels of FGF21 mRNA, in agreement with the
almost undetectable expression of FGF21 in human adipose tissue (13, 39, 40). How-
ever, we found that the NNRTI efavirenz and the INSTIs elvitegravir and raltegravir
signiﬁcantly induced FGF21 mRNA expression (Fig. 2A); treatment with lopinavir-
ritonavir also produced a trend towards increased FGF21 expression, although the
Moure et al. Antimicrobial Agents and Chemotherapy
June 2018 Volume 62 Issue 6 e00029-18 aac.asm.org 4
 o
n
 June 14, 2018 by UNIV DE LLEIDA
http://aac.asm
.org/
D
ow
nloaded from
 
differences did not reach statistical signiﬁcance (P  0.09). Again, these drugs exerted
reciprocal repressive effects on KLB mRNA expression. As was the case for hepatic cells,
they also induced effects on the expression of the ER stress/oxidative stress markers
CHOP10 and HSPA5 that largely paralleled their effects on FGF21 expression; the one
exception was elvitegravir, which had no effect on HSPA5 expression (Fig. 2A). A
concentration-response analysis of the drugs that showed signiﬁcant effects at single
concentrations indicated that efavirenz caused overt reciprocal FGF21 induction/KLB
repression effects at 5 M, lopinavir-ritonavir at 20 M, and elvitegravir in the 1 to 2 M
range (see Fig. S2). The concentration-response effects of the three types of drug
treatments remarkably paralleled those for the induction of CHOP10. However, only
lopinavir-ritonavir induced the ER stress marker HSPA5.
Considering that the effects of treating adipocytes with drugs throughout their
adipogenic differentiation may cause secondary effects related to alterations in the
overall differentiation process, we used a second experimental paradigm in which fully
differentiated human adipocytes were exposed to the drugs for 24 h. The results of
these experiments were very similar to those found previously in adipogenic cells
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P  0.05; **, P  0.01, and ***, P  0.001 for each drug treatment versus control.
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chronically treated with drugs: very low basal expression of FGF21 and signiﬁcant FGF21
induction and KLB repression in response to lopinavir-ritonavir and elvitegravir (Fig. 2B).
We also found that the same drugs that induced FGF21 expression and KLB repression
induced the ER stress/oxidative stress markers CHOP10 and HSPA5; the one exception
was the absence of an effect of elvitegravir on HSPA5. The ER stress inducers thapsi-
gargin and tunicamycin mimicked the FGF21 induction and KLB repression elicited by
these drugs. Notably, in this experimental setting, rilpivirine caused a signiﬁcant
induction of CHOP10 and HSPA5 expression, but this did not translate into changes in
FGF21 or KLB gene expression (Fig. 2B). As was the case in the ﬁrst experimental setting,
a concentration-response analysis showed that efavirenz, lopinavir-ritonavir, and elvite-
gravir caused minor effects on FGF21 expression that paralleled changes in CHOP10 and
HSPA5 expression, but only at high concentrations (10 to 20 M) (see Fig. S3).
The low range of FGF21 mRNA expression in human adipocytes was reﬂected in the
very low levels of FGF21 in the cell culture medium, which precluded reliable mea-
surements of FGF21 concentration changes in response to drugs, in contrast with that
in hepatic and muscle cells.
Considering that KLB gene expression is particularly sensitive to the differentiation
status of adipocytes, we investigated whether the repression of KLB mRNA expression
induced by drugs was attributable to impaired KLB gene transcription. To this end, we
transfected preadipocytes with a luciferase reporter plasmid driven by the KLB gene
promoter and exposed the cells to drugs. This analysis showed that whereas rosiglita-
zone (used as a positive control for KLB gene regulation) (27, 41) induced KLB gene
transcription, lopinavir-ritonavir and efavirenz signiﬁcantly downregulated KLB pro-
moter activity, as was also the case for the ER stress positive controls, tunicamycin and
thapsigargin (Fig. 2C).
Effects of antiretroviral drugs on FGF21 expression in human skeletal muscle
cells. Although skeletal muscle is not considered to be a source or target of FGF21, a
recent report indicated that FGF21 expression is enhanced in muscle from HIV patients
(7), a phenomenon also reported in other conditions of skeletal muscle stress such as
mitochondrial diseases (19, 20). KLB expression was virtually undetectable in differen-
tiated human LHCN-M2 skeletal muscle cells, as expected. FGF21 expression was also
very low under control conditions, but PIs (with the exception of atazanavir) and
efavirenz caused a dramatic induction of FGF21 expression, whereas NRTIs, NNRTIs
(other than efavirenz), and maraviroc had no effect (Fig. 3A). Efavirenz and the same PIs
that caused FGF21 upregulation induced the expression of CHOP10 and HSPA5. Thap-
sigargin and tunicamycin also induced FGF21 expression in muscle cells.
Efavirenz, the lopinavir-ritonavir combination, and the ER stress/oxidative stress
inducers thapsigargin and tunicamycin caused a signiﬁcant induction of the release of
FGF21 protein by LHCN-M2 myotubes into culture medium, paralleling the results
found for FGF21 mRNA expression (Fig. 3B).
Effects of inhibitors of ER stress and oxidative stress on the action of antiret-
roviral drugs on FGF21 and KLB expression in human adipocytes. Our data
demonstrating that several antiretroviral drugs, mainly PIs (e.g., lopinavir-ritonavir) and
efavirenz, acted in the same manner as ER stress/oxidative stress to cause the induction
of FGF21 expression and repression of KLB expression strongly suggest that ER stress
and oxidative stress drive the reciprocal alterations in the FGF21 system. To test this, we
used 4-phenylbutyrate (PBA), an inhibitor of ER stress, and 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (Trolox), a vitamin E analog with antioxidant
properties (Fig. 4). PBA signiﬁcantly impaired the induction of ER stress. Trolox reduced
thapsigargin- and tunicamycin-induced expression of CHOP10, but not the thapsigargin-
and tunicamycin-induced expression of HSPA5, thus excluding HSPA5 as an oxidative stress
marker; this contrasts with the dual responsiveness of CHOP10 to both ER and oxidative
stress. PBA suppressed the induction of FGF21 and repression of KLB expression by
thapsigargin and tunicamycin, thus conﬁrming that ER stress is capable of causing FGF21
upregulation and KLB downregulation. Both PBA and Trolox impaired the induction of
CHOP10 and HSPA5 by lopinavir-ritonavir, suggesting that PIs are capable of causing
Moure et al. Antimicrobial Agents and Chemotherapy
June 2018 Volume 62 Issue 6 e00029-18 aac.asm.org 6
 o
n
 June 14, 2018 by UNIV DE LLEIDA
http://aac.asm
.org/
D
ow
nloaded from
 
both ER and oxidative stress. Similarly, PBA and Trolox blunted the induction of FGF21
by lopinavir-ritonavir and elvitegravir. However, neither PBA nor Trolox affected the
repression of KLB expression by these drugs, indicating that pathways other than ER
stress/oxidative stress may be speciﬁcally involved in downregulating KLB in response
to PIs. The downregulation of KLB elicited by elvitegravir was suppressed by PBA but
was unaffected by Trolox. Efavirenz treatment had relatively modest effects in adi-
pocytes under these conditions. Although it did signiﬁcantly induce CHOP10 and HSPA5
expression, it caused only a minor induction of FGF21. These effects were relatively
insensitive to PBA and Trolox, which at best exerted modest inhibitory actions.
Collectively, these data indicate that PIs, as well as elvitegravir and efavirenz, induce
FGF21 expression through mechanisms involving ER and oxidative stress. However,
although ER stress may induce KLB repression, other pathways are likely also involved
in the repressive effect of PIs on KLB expression.
DISCUSSION
The results of the current study indicate that some antiretroviral drugs belonging to
distinct classes alter the expression of FGF21 and the FGF21 coreceptor KLB in human
cells. We found that modiﬁcations in the expression of FGF21 and KLB caused by drugs
parallel those observed in HIV patients undergoing antiretroviral treatment: an induc-
tion of FGF21 levels and a repression of KLB expression (6, 7, 13). Moreover, the
observed alterations are systematically reciprocal: those drugs (and drug concentra-
tions) that induce FGF21 expression and release are largely the same as those that
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FIG 3 Effects of antiretroviral drugs, tunicamycin, and thapsigargin on the expression of FGF21, CHOP10, and HSPA5 mRNAs and FGF21 release into the cell
culture medium in human LHCN-M2 skeletal muscle cells differentiated in culture. LHCN-M2 myotubes differentiated in culture were treated for 24 h, as
indicated, with the following drugs: zidovudine (AZT), 100 M; stavudine (D4T), 100 M; tenofovir disoproxil fumarate (TDF), 5 M; nevirapine (NVP), 20 M;
efavirenz (EFV), 50 M; rilpivirine (RPV), 10 M; lopinavir-ritonavir 4:1 (LPV/r), 20 M; ritonavir (RTV), 20 M; lopinavir (LPV), 20 M; nelﬁnavir (NFV), 20 M;
atazanavir (ATV), 50 M; maraviroc (MRV), 4 M; tunicamycin (TUN), 2 M; thapsigargin (THAP), 2 M. (A) mRNA levels are presented as means  SEM from
4 to 5 independent experiments and are expressed relative to values for control cells (deﬁned as 1). (B) FGF21 protein levels in cell culture medium. Data are
presented as means  SEM from 4 to 5 independent experiments. *, P  0.05; **, P  0.01, and ***, P  0.001 for each drug treatment versus control.
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FIG 4 Effects of the ER stress-response inhibitor PBA and the antioxidant Trolox on the actions of
antiretroviral drugs on the expression of FGF21, KLB, CHOP10, and HSPA5mRNAs in human SGBS adipocytes
differentiated in culture. SGBS human preadipocytes were differentiated in culture into adipocytes and
treated for 24 h with the following drugs: efavirenz (EFV), 20 M; rilpivirine (RPV), 10 M; lopinavir-ritonavir
4:1 (LPV/r), 20 M; elvitegravir (ELV) 10 M; tunicamycin (TUN), 2 M; thapsigargin (THAP), 2 M. Where
indicated, cells were cultured in the presence of 2 mM PBA or 1 mM Trolox. Data are presented as means SEM
from 4 to 5 independent experiments and are expressed relative to values for control cells (deﬁned as 1). *, P
 0.05; **, P  0.01, and ***, P  0.001 for each drug treatment versus control; #, P  0.05; ##, P  0.01;
###, P  0.001 for the effects of PBA or Trolox.
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repress KLB expression. NRTIs and the viral entry inhibitor maraviroc were universally
neutral toward the FGF21/KLB system. PIs, the NNRTI efavirenz, and the INSTI elvite-
gravir were the drugs most capable of eliciting FGF21 induction/KLB repression effects,
which otherwise followed a pattern dictated largely by the speciﬁc drug and the cell
type assayed. The induction of FGF21 and repression of KLB expression in hepatic and
adipose cells reﬂected the effects on gene transcription. Therefore, and on the basis of
the remarkable concordance between the effects found here in vitro for several
antiretroviral drugs and the alterations in the FGF21/KLB system found in HIV patients,
attention should be paid to the potential of particular drugs in the ART cocktails to
disturb the FGF21 system.
Subsequently, we explored the intracellular-mediated mechanisms explaining the
negative effects of antiretroviral drugs on the FGF21/KLB system. In general, the drug
treatments that elicited FGF21 induction/KLB repression in human hepatic, adipose,
and muscle cells were also those that induced ER stress/oxidative stress. Speciﬁc
pharmacological induction of ER stress/oxidative stress mimicked the effects of the
drugs on the FGF21/KLB system. Moreover, the induction of ER stress/oxidative stress
marker genes closely paralleled FGF21 induction and KLB repression in concentration-
response analyses of lopinavir-ritonavir and elvitegravir. However, elvitegravir induced
FGF21 and repressed KLB at concentrations lower than those capable of eliciting overt
ER stress in hepatic cells, suggesting that pathways other than ER stress may be
additionally involved in elvitegravir effects. The results obtained using inhibitors of ER
stress and oxidative stress support the involvement, but not the exclusivity, of these
stress pathways in the cellular actions of antiretroviral drugs on the FGF21/KLB system.
Abnormally high FGF21 levels are considered a marker of disturbed metabolism in
non-HIV-infected patients with obesity, diabetes, or congenital lipodystrophy (15, 16,
42), whereas KLB repression is associated with an impairment of glucose uptake and
other health effects mediated by FGF21 (27). Studies in distinct HIV patient cohorts
have consistently reported that elevated FGF21 levels are associated with indicators of
insulin resistance, such as homeostatic model assessment of insulin resistance (HOMA-
IR), insulinemia, and glycemia (6–8, 16). Lifestyle interventions in HIV patients that
achieve metabolic improvement are also associated with a decline in FGF21 levels that
correlates with indications of improved energy metabolism (8). Further studies will be
needed to assess if treatment only with antiretroviral drugs identiﬁed as “neutral” in our
cell-based study protects HIV patients against abnormalities in the FGF21/KLB system
and concomitant metabolic disturbances.
The present in vitro study is obviously limited with respect to the translation of
results to considerations of the impact of patient treatments on the FGF21 system. The
average plasma concentration of drugs in patients under standard treatment regimens
is approximately 10 M for efavirenz and lopinavir and 5 M for elvitegravir (43–45),
indicating that the effects on human adipocytes and muscle cells in vitro reported here
occur in a concentration range that may have in vivo relevance. However, in our study,
efavirenz and elvitegravir were added to adipocyte and myotube cell cultures in
serum-free or low-serum-containing medium—culture conditions that are required for
the in vitro differentiation of human adipocytes and muscle cells but may result in
higher availability of the drugs owing to a lack of binding to proteins. Consistent with
this interpretation, the concentrations of efavirenz and elvitegravir required to cause
FGF21 induction/KLB repression in hepatic cells, which require 10% fetal bovine serum
(FBS), were higher, implying that the presence of high levels of drug-binding proteins
in the medium reduces the actual amount of drug available to the cell. On the other
hand, one study that measured the accumulation of certain antiretroviral drugs in
adipose tissues showed concentrations close to 100 nmol/g tissue for efavirenz and 1
nmol/g for the PI ritonavir (46); thus, intracellular concentrations, at least for efavirenz,
may be higher than the plasma concentrations.
In summary, several antiretroviral drugs used in HIV therapy and belonging to
distinct drug classes have been identiﬁed for the ﬁrst time as triggering disturbances in
the FGF21/KLB system in human hepatic, adipose, and muscle cells in culture. These
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drugs cause reciprocal FGF21 induction/KLB repression alterations that commonly
occur in HIV patients undergoing antiretroviral treatment. ER stress/oxidative stress
mechanisms appear to be involved in these effects. Considering the potential role of
disruptions in the FGF21 system in metabolic, cardiovascular, and bone-related alter-
ations, the data presented here could inspire further research designed to improve
antiretroviral treatments so as to minimize the adverse effects of antiretroviral agents
in HIV-1-infected patients.
MATERIALS AND METHODS
Reagents. The following chemicals/drugs were used: zidovudine (GlaxoSmithKline), stavudine
(Bristol-Myers Squibb), tenofovir disoproxil fumarate (Gilead Sciences), nevirapine (Boehringer Ingel-
heim), efavirenz (Bristol-Myers Squibb), rilpivirine (Janssen Pharmaceuticals, Inc.), ritonavir (Abbott
Laboratories), lopinavir (Abbott Laboratories), nelﬁnavir (Agouron), atazanavir (Bristol-Myers Squibb),
raltegravir (sc-364600; Santa Cruz), elvitegravir (Gilead Sciences), maraviroc (Pﬁzer), tunicamycin (T7765;
Sigma-Aldrich Biotechnology), thapsigargin (T9033; Sigma-Aldrich), 4-phenylbutyric acid ([PBA] P21005;
Sigma-Aldrich), 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid ([Trolox] 648471; Calbiochem),
and rosiglitazone (ALX-350-125; Alexis Biochemicals). The reagents for cell culture were from Sigma-
Aldrich, whereas media and FBS were from Life Technologies. For initial assessments of the effects of
antiretroviral drugs prior to concentration-response analyses, the drugs were used at the highest
concentrations that did not cause cytotoxicity in speciﬁc cell systems. The drugs were dissolved using
dimethyl sulfoxide (DMSO) as the vehicle. Controls included amounts of DMSO (0.1% DMSO of total cell
medium volume) equal to those used in drug-treated cells.
Cell culture. The HepG2 cell line (ATCC HB-8065), used for studies on human hepatic cells, was
cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) containing 10% FBS. The human SGBS preadi-
pocyte cell line (47) was used for studies on adipocytes. Human SGBS preadipocytes were cultured and
differentiated to adipocytes as previously reported (36). Brieﬂy, SGBS preadipocytes were maintained in
DMEM/F12 containing 10% FBS. After the cells had become conﬂuent, adipogenic differentiation was
initiated by ﬁrst incubating the cells for 6 days in serum-free medium containing 20 nM insulin, 0.2 nM
triiodothyronine (T3), and 100 nM cortisol, supplemented with 25 nM dexamethasone and 500 M
3-isobutyl-methylxantine. The cells were subsequently switched to adipogenic differentiation medium
containing insulin, T3, and cortisol only and maintained for up to 10 days, at which point, more than 90%
of the cells had acquired a differentiated adipocyte morphology, as evidenced by lipid droplet accumu-
lation. Depending on the experimental design, the cells were treated with drugs throughout the 10-day
differentiation process or acutely for 24 h once cells had differentiated. For studies on human skeletal
muscle cells, LHCN-M2 myoblastic cells were differentiated to myotubes as previously reported (23).
Brieﬂy, myoblastic LHCN-M2 cells were cultured in DMEM/medium 199 containing 15% FBS and
supplemented with 60 g/ml ZnSO4, 14 g/ml vitamin B12, 55 g/ml dexamethasone, 30 g/ml human
hepatocyte growth factor, and 10 g/ml basic ﬁbroblast growth factor (FGF2). When cells reached80%
conﬂuence, the culture medium was replaced with fresh DMEM/medium 199 supplemented with 0.5%
FBS, 1 mg/ml insulin, 10 mg/ml apo-transferrin, and 55 g/ml dexamethasone. After culturing for 2 days,
the medium was replaced with DMEM/medium 199 supplemented with 55 g/ml dexamethasone, and
the cells were further cultured for 10 days, at which point, more than 90% had acquired a
differentiated phenotype on the basis of their multinucleated fused myotube morphology. LHCN-M2
myotubes were exposed to drugs for 24 h. For the analysis of FGF21 protein levels, the cell culture
medium was harvested 24 h after the replacement of the cell culture medium in the presence of the
drugs tested.
RNA isolation, conventional reverse transcription-PCR, and quantitative reverse transcription-
PCR. Total RNA was extracted from cells using an afﬁnity column-based method (Macherey-Nagel) as
previously described (36). Reverse transcription was performed in a total volume of 20 l using random
hexamer primers (Applied Biosystems) and 0.5 g total RNA. PCR was performed on an ABI/Prism 7700
sequence detector system using 25 l of a reaction mixture containing 1 l of cDNA, 12.5 l of TaqMan
Universal PCR master mix, 250 nM probes, and 900 nM primers from an Assays-on-Demand gene
expression assay mix (TaqMan; Applied Biosystems). The following Assay-on-Demand probes from Life
Technologies were used: FGF21, Hs00173927; KLB, Hs00545621; CHOP10, Hs99999172;HSPA5, Hs99999174; HPRT,
Hs99999909; RPLP0, Hs99999902; and 18S rRNA, Hs99999901. Controls with no RNA, primers, or reverse
transcriptase were included in each set of experiments. The relative amount of individual mRNAs was
calculated using the comparative (2ΔΔCT) method and normalized to that of the reference control gene
(HPRT mRNA) according to the manufacturer’s instructions. Each sample was run in duplicates, and
the mean value of duplicates was used in calculations. Parallel calculations performed using other
reference control genes (RPLP0 mRNA and 18S rRNA) yielded essentially the same results.
Plasmid constructions and dual luciferase reporter assays. For studies on the transcriptional
activity of FGF21 and KLB genes, HepG2 hepatic cells and HIB1B adipogenic cells (48), respectively, were
grown in 24-well plates and transiently transfected at 50% conﬂuence with the corresponding
promoter-luciferase reporter plasmids using Lipofectamine (Invitrogen). The reporter plasmid 1497-
FGF21-Luc, containing a DNA fragment corresponding to positions 1,497 to 5 of the 5= region of the
mouse Fgf21 gene linked to the ﬁreﬂy luciferase gene, and a 77-FGF21-Luc mutant construct contain-
ing only the 77/5 region of the FGF21 gene, were reported previously (48). The reporter plasmid
driven by the KLB gene promoter, containing a DNA fragment corresponding to positions1,055 to45,
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was obtained from SwitchGear Genomics. Cells were also cotransfected with a pRL-CMV expression
vector for Renilla luciferase (Promega). Each transfection condition was assayed in triplicates. The cells
were incubated for 48 h after transfection and then incubated with or without drugs, as indicated in the
text, for an additional 24 h before harvesting. Luciferase activity was measured on a Glomax 96
microplate luminometer using a dual luciferase reporter assay system kit (Promega). Promoter construct-
driven luciferase activity was normalized to that of Renilla luciferase, used as a control for variations in
transfection efﬁciency.
FGF21 protein analysis. FGF21 protein levels in cell culture media were determine using an
enzyme-linked immunosorbent assay (ELISA) speciﬁc for human FGF21 (RD191108200R; Biovendor) as
described previously (48). For cultures of HepG2 cells, the medium had to be concentrated (1,000 l to
50 l) using centrifugal ﬁlters (UFC 50195; Amicon) to achieve measurable amounts of FGF21 in the
ELISAs.
Statistical analysis. In studies comparing high concentrations of different drugs, statistical analyses
were performed using Student’s t tests to compare the effects of each drug with that of the control. In
the case of concentration-response studies, statistical analyses were performed using a one-way analysis
of variance (ANOVA) followed by a Dunnett’s test. Differences with P values of 0.05 were considered
statistically signiﬁcant.
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